BASEL, Switzerland (Reuters) - Roche , the maker of the Tamiflu flu drug, missed forecasts with a 29 percent drop in first-half net profit, hit by costs related to its $47 billion acquisition of Genentech.
Reuters: Business News, Reuters: Business
Wed, 07/22/2009 - 10:46pm
BASEL, Switzerland (Reuters) - Roche , the maker of the Tamiflu flu drug, missed forecasts with a 29 percent drop in first-half net profit, hit by costs related to its $47 billion acquisition of Genentech.